Data documento
06/05/2024

Título
3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells

Autor(es)
Vital P.D.S. - Bonatelli M, - Dias M.P. - de Salis L.V.V. - Pinto M.T. - Baltazar F. - Maria-Engler S.S. - Pinheiro C.

Palavras chave
drug resistance - melanoma - metabolism - proto-oncogene protein B-raf - vemurafenib

Resumo
(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, even with contemporary therapeutic alternatives. Highly proliferative tumors often rely on glycolysis to sustain their aggressive phenotype. 3-bromopyruvate (3BP) is a promising glycolysis inhibitor reported to mitigate resistance in tumors. This study aimed to evaluate the potential of 3BP as an antineoplastic agent for PLX-resistant melanoma treatment. (2) The effect of 3BP alone or in combination with PLX on viability, proliferation, colony formation, cell death, migration, invasion, epithelial-mesenchymal marker and metabolic protein expression, extracellular glucose and lactate, and reactive species were evaluated in two PLX-resistant melanoma cell lines. (3) 3BP treatment, which was more effective as monotherapy than combined with PLX, disturbed the metabolic and epithelial-mesenchymal profile of PLX-resistant cells, impairing their proliferation, migration, and invasion and triggering cell death. (4) 3BP monotherapy is a potent metabolic-disrupting agent against PLX-resistant melanomas, supporting the suppression of the malignant phenotype in this type of neoplasia.

Citação
Vital PDS, Bonatelli M, Dias MP, de Salis LVV, Pinto MT, Baltazar F, Maria-Engler SS, Pinheiro C. 3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. Int J Mol Sci. 2022 Dec 9;23(24):15650. doi: 10.3390/ijms232415650. PMID: 36555289; PMCID: PMC9779063.

Data documento
06/05/2024

Título
Alpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patients

Autor(es)
Teixeira S.A. - Burim R.V. - Viapiano M.S. - Bidinotto L.T. - Nagashi Marie S.K. - Fleury Malheiros S.M. - Oba-Shinjo S.M. - Andrade A.F. - Carlotti C.G.

Palavras chave
ITGA2 - brain microenvironment - extracellular matrix - invasion - low grade glioma - single nucleotide polymorphism - tumor progression

Resumo
Integrins are heterodimeric transmembrane glycoproteins resulting from the non-covalent association of an α and β chain. The major integrin receptor for collagen/laminin, α2β1 is expressed on a wide variety of cell types and plays an essential role in the adhesion of normal and tumor cells to the extracellular matrix. Integrin-triggered signaling pathways promote the invasion and survival of glioma cells by modifying the brain microenvironment. In this study, we investigated the association of a specific genetic polymorphism of integrin α2β1 with the incidence of diffusely infiltrating astrocytoma and the progression of these tumors. Single-nucleotide polymorphism in intron 7 of the integrin ITGA2 gene was examined in 158 patients and 162 controls using polymerase chain reaction and restriction enzyme analysis. The ITGA2 genotype +/+ (with a BglII restriction site in both alleles) exhibited higher frequency in grade II astrocytoma compared to control (P = 0.02) whereas the genotype -/- (lacking the BglII site) correlated with the poorest survival rate (P = 0.04). In addition, in silico analyses of ITGA2 expression from low-grade gliomas (LGG, n = 515) and glioblastomas (GBM, n = 159) indicated that the higher expression of ITGA2 in LGG was associated with poor overall survival (P < 0.0001). However, the distribution of integrin ITGA2 BglII genotypes (+/+, +/-, -/-) was not significantly different between astrocytoma subgroups III and IV (P = 0.65, 0.24 and 0.33; 0.29, 0.48, 0.25, respectively) compared to control. These results suggest a narrow association between the presence of this SNP and indicate that further studies with larger samples are warranted to analyze the relation between tumor grade and overall survival, highlighting the importance of determining these polymorphisms for prognosis of astrocytomas.

Citação
Teixeira SA, Burim RV, Viapiano MS, Bidinotto LT, Nagashi Marie SK, Fleury Malheiros SM, Oba-Shinjo SM, Andrade AF, Carlotti CG. Alpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patients. Front Oncol. 2022 Jul 22;12:914156. doi: 10.3389/fonc.2022.914156. PMID: 35936750; PMCID: PMC9353741.

Data documento
06/05/2024

Título
ANÁLISE VACINAL DE ESTUDANTES EM UMA FACULDADE DE MEDICINA

Autor(es)
Modiano P,, Herrero A.L.O. - Silveira A.F. - Piai R.C. - Veríssimo V.H.M. - Moreira M.L.F.F. - Fabbro N. - Pileggi G.S.

Palavras chave
Estudantes de medicina - Conhecimento - Risco - Vacinação - Vacinas

Resumo
Objetivo: O estudo analisa a situação vacinal dos estudantes de medicina de uma faculdade do interior de São Paulo, além de verificar seu conhecimento em relação à imunização. Método: Foi realizada a análise na carteira vacinal de 277 estudantes de medicina e disponibilizado um questionário autoaplicável. A análise dos dados foi conduzida de maneira estatística descritiva para interpretação dos resultados. Resultados: Verificou-se que mais da metade dos estudantes apresentam carteiras vacinais desatualizadas e poucos conhecem quais vacinas são indicadas aos profissionais de saúde, embora mais da metade dos estudantes reconheça o risco de contágio e transmissão de doenças relacionadas ao esquema vacinal incompleto. Conclusão: Esses resultados demonstram a necessidade de conscientização dos acadêmicos de medicina quanto à atualização de seus cartões vacinais e do aprofundamento do conhecimento e domínio sobre o tema vacinação.

Citação
Modiano P, Herrero ALO, Silveira AF, Piai RC, Veríssimo VHM, Moreira MLFF, Fabbro N, Pileggi GS. Análise vacinal de estudantes em uma faculdade de medicina. Rev Enferm Atenção Saúde [Internet]. 2023 [acesso em:____]; 12(2):e202377. DOI: https://doi.org/ 10.18554/reas.v12i2.5681

Data documento
06/05/2024

Título
Aspectos psicológicos na recidiva do câncer colorretal: revisão integrativa

Autor(es)
Ramos, L. N. de S. - Ducatti, M.

Palavras chave
Neoplasia - Psico-oncologia - Recidiva

Resumo
Objetivo: Realizar uma revisão integrativa acerca dos aspectos psicológicos que envolvem a recidiva em pacientes após o tratamento de câncer colorretal e identificar as intervenções e instrumentos de maior validade dentro das estratégias propostas no campo da psicologia. Métodos: Trata-se de uma revisão integrativa, realizada nas bases de dados Pubmed, Cochrane Library e Biblioteca Virtual de Saúde (BVS). Utilizou-se os seguintes descritores para a realização da estratégia de busca: Recurrence, Psychological Aspects e Colorectal Neoplasm. Resultados: Após a inserção da estratégia de busca nas bases de dados, 19 artigos foram encontrados. Realizou a análise dos artigos com base nos critérios de inclusão e exclusão e 11 estudos foram selecionados para este trabalho. Considerações finais: Os resultados evidenciaram escassez de estudos sobre o tema. Identificou-se que a principal demanda psicológica identificada foi o medo; e que se faz o uso de diversos instrumentos para quantificar queixas e aspectos psicológicos sobre o tema citado.

Citação
RamosL. N. de S., & DucattiM. (2023). Aspectos psicológicos na recidiva do câncer colorretal: revisão integrativa. Revista Eletrônica Acervo Saúde, 23(3), e10662. https://doi.org/10.25248/reas.e10662.2023

Data documento
06/05/2024

Título
Clinical Course, Genetic, and Immunohistochemical Characterization of Solid Pseudopapillary Tumor of the Pancreas (Frantz Tumors) in a Brazilian Cohort

Autor(es)
Tostes F.T. - de Carvalho P.F.D.C. - Araújo R.L.C. - Ribeiro R.C. - Apodaca-Torrez F.R. - Lobo E.J. - Gomes D.B.D. - Callegaro-Filho D. - Schvartsman G. - Moura F. - Schraibman V. - Goldenberg A. - de Lima F.T. - Segatelli V. - Uson Junior P.L.S.

Palavras chave
Frantz tumor - Li-Fraumeni syndrome - pancreatic tumor - solid pseudopapillary pancreatic neoplasm

Resumo
Frantz tumors or solid pseudopapillary pancreatic neoplasm (SPN) are rare exocrine neoplasms that carry a favorable prognosis; they represent up to 3% of all tumors located in the region of the pancreas and have specific age and gender predispositions. In recent years, the rising curve of diagnosis is entitled to the evolution and access of diagnostic imaging. In this paper, we have retrospectively reviewed and described the clinical course of 40 patients with SPN from three institutions in Brazil, who had their diagnosis between 2005 and 2020, and analyzed the clinicopathological, genetic, and surgical aspects of these individuals. In accordance with the literature, most patients were women, 60% with unspecified symptoms at diagnosis, with tumors mainly located in the body and tail of the pancreas, of whom 70% underwent a distal pancreatectomy with sparing splenectomy as a standard procedure, and none of the cases have experienced recurrence to date. Surgery still remains the mainstay of treatment given the low metastatic potential, but more conservative approaches as observed in this cohort are evolving to become the standard of care. Herein, we present an in-depth analysis of cases focusing on the latest literature and report some of the smallest tumor cases in the literature. To our knowledge, this is the first report evaluating germline genetic testing and presenting a case of detected Li-Fraumeni syndrome.

Citação
Tostes FT, de Carvalho PFDC, Araújo RLC, Ribeiro RC, Apodaca-Torrez FR, Lobo EJ, Gomes DBD, Callegaro-Filho D, Schvartsman G, Moura F, Schraibman V, Goldenberg A, de Lima FT, Segatelli V, Uson Junior PLS. Clinical Course, Genetic, and Immunohistochemical Characterization of Solid Pseudopapillary Tumor of the Pancreas (Frantz Tumors) in a Brazilian Cohort. Genes (Basel). 2022 Oct 6;13(10):1809. doi: 10.3390/genes13101809. PMID: 36292694; PMCID: PMC9601385.

Data documento
06/05/2024

Título
Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines

Autor(es)
Gomes I.N.F. - da Silva-Oliveira R.J. - da Silva L.S. - Martinho O. - Evangelista A.F. - van Helvoort Lengert A. - Leal L.F. - Silva V.A.O. - Dos Santos S.P. - Nascimento F.C. - Lopes Carvalho A. - Reis R.M.

Palavras chave
EGFR - biomarkers - cetuximab - drug resistance - head and neck tumors - in vitro - pre-clinical

Resumo
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC. Herein, we address the molecular mechanisms underlying cetuximab resistance in an in vitro model. We established a cetuximab resistant model (FaDu), using increased cetuximab concentrations for more than eight months. The resistance and parental cells were evaluated for cell viability and functional assays. Protein expression was analyzed by Western blot and human cell surface panel by lyoplate. The mutational profile and copy number alterations (CNA) were analyzed using whole-exome sequencing (WES) and the NanoString platform. FaDu resistant clones exhibited at least two-fold higher IC50 compared to the parental cell line. WES showed relevant mutations in several cancer-related genes, and the comparative mRNA expression analysis showed 36 differentially expressed genes associated with EGFR tyrosine kinase inhibitors resistance, RAS, MAPK, and mTOR signaling. Importantly, we observed that overexpression of KRAS, RhoA, and CD44 was associated with cetuximab resistance. Protein analysis revealed EGFR phosphorylation inhibition and mTOR increase in resistant cells. Moreover, the resistant cell line demonstrated an aggressive phenotype with a significant increase in adhesion, the number of colonies, and migration rates. Overall, we identified several molecular alterations in the cetuximab resistant cell line that may constitute novel biomarkers of cetuximab response such as mTOR and RhoA overexpression. These findings indicate new strategies to overcome anti-EGFR resistance in HNSCC.

Citação
Gomes INF, da Silva-Oliveira RJ, da Silva LS, Martinho O, Evangelista AF, van Helvoort Lengert A, Leal LF, Silva VAO, Dos Santos SP, Nascimento FC, Lopes Carvalho A, Reis RM. Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines. Cells. 2022 Jan 4;11(1):154. doi: 10.3390/cells11010154. PMID: 35011716; PMCID: PMC8750399.

Data documento
06/05/2024

Título
Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets

Autor(es)
Marques R.F. - Moreno D.A. - da Silva L. - Leal L.F. - de Paula F.E. - Santana I. - Teixeira G. - Saggioro F. - Neder L. - Junior C.A. - Mançano B. - Reis R.M.

Palavras chave
immune checkpoints - immune profile - immunotherapy - medulloblastoma - nCounter mRNA expression assay

Resumo
Introduction: Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection, craniospinal radiation, and chemotherapy. However, many patients do not respond to therapy, and most suffer severe side effects. Cancer immunotherapy targeting immune checkpoints (IC) (PD-1, PD-L1, and CTLA4) has been getting disappointing outcomes in brain tumors. Nevertheless, other less explored immune checkpoints may be promising candidates for medulloblastoma therapy. Objectives: In the present study, we aimed to characterize the expression profile of 19 immune checkpoints in medulloblastoma. Methods: We analyzed 88 formalin-fixed paraffin-embedded medulloblastomas previously classified for each molecular subgroup and three non-tumoral brain tissue. mRNA levels of 19 immune checkpoint-related genes were quantified using the nCounter (PanCancer Immune Profiling Panel) assay. Further in silico analysis was performed in two larger public microarray datasets, one of which enabled comparisons between tumoral and non-tumoral tissues. Immunohistochemistry of PD-L1 was performed in a subset of cases. Microsatellite instability was also molecularly analyzed. Results: We observed an absence of expression of the canonic ICs, namely PDCD1 (PD-1), CD274 (PD-L1), and CTLA4, as well as CD80, CD86, BTLA, IDO1, CD48, TNFSF14, CD160, CEACAM1, and CD244. PD-L1 protein expression was also practically absent. We found higher mRNA levels of CD24, CD47, CD276 (B7-H3), and PVR, and lower mRNA levels of HAVCR2, LAG3, and TIGIT genes, with significant differences across the four molecular subgroups. Compared to the non-tumor tissues, the expression levels of CD276 in all subgroups and CD24 in SHH, Group 3, and Group 4 subgroups are significantly higher. The in silico analysis confirmed the expression profile found in the Brazilian cohort, including the lower/absent expression of the canonic ICs. Moreover, it confirmed the overexpression of CD24 and CD276 in medulloblastomas compared with the non-tumor tissue. Additionally, CD276 and CD24 high levels were associated with worse survival. Conclusion: These results highlight the low or absence of mRNA levels of the canonic targetable ICs in medulloblastomas. Importantly, the analysis revealed overexpression of CD24 and CD276, which can constitute prognostic biomarkers and attractive immunotherapy targets for medulloblastomas.

Citação
Marques RF, Moreno DA, da Silva L, Leal LF, de Paula FE, Santana I, Teixeira G, Saggioro F, Neder L, Junior CA, Mançano B, Reis RM. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets. Front Immunol. 2023 Feb 7;14:1062856. doi: 10.3389/fimmu.2023.1062856. PMID: 36825029; PMCID: PMC9941636.

Data documento
02/05/2024

Título
ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer

Autor(es)
Cavagna, R.O. - Zaniolo, B. G. - Paula, F.E. - Berardinelli, G.N. - Santana, I. - Silva, E.C.A. - Dias, J. M. - Jacinto, A.A. - Oliveira, R.E.N.N. - Marchi, P. - Leal, L.F. - Reis, R.M.

Palavras chave
Brazil - ERBB2 - exon 20 insertions - non-small cell lung cancer

Resumo
ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non-small cell lung cancer (NSCLC) patients from Barretos Cancer Hospital that were indicated to require routine lung cancer molecular testing. ERBB2 exon 20 insertions were evaluated by a targeted panel using next-generation sequencing (NGS). Clinicopathological and molecular data were collected from patient medical records. Among the 722 NSCLC patients, 85.2% had lung adenocarcinomas, 53.9% were male, 66.8% were quitter or current smokers, and 63.2% were diagnosed at an advanced stage of the disease. We identified 0.8% (6/722) of patients who harbored the insertion p. (Tyr772_Ala775dup) at exon 20 of the ERBB2 gene. All ERBB2 mutated patients were diagnosed with lung adenocarcinoma, were never smokers, and wild-type for EGFR, KRAS, and ALK hotspot alterations. Less than 1% of Brazilian NSCLC patients harbor ERBB2 exon 20 insertions, yet they could benefit in future from the new drugs in development.

Citação
de Oliveira Cavagna R, Zaniolo BG, de Paula FE, Berardinelli GN, Santana I, da Silva ECA, Dias JM, Jacinto AA, da Nóbrega Oliveira REN, de Marchi P, Leal LF, Reis RM. ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer. Thorac Cancer. 2022 Dec;13(23):3402-3407. doi: 10.1111/1759-7714.14605. Epub 2022 Oct 17. PMID: 36251951; PMCID: PMC9715798.

Data documento
06/05/2024

Título
Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response?

Autor(es)
Oliveira A.F. - Tansini A. - Toledo T. - Balceiro R. - Lee M.L.M. - Villela N. - Ikeuty P. - Metze K. - Lopes L.F. - Lorand-Metze I.

Palavras chave
azacytidine - immunophenotyping - juvenile myelomonocytic leukaemia - treatment

Resumo
5-Azacitidine has been used before stem cell transplantation in juvenile myelomonocytic leukaemia (JMML) patients. Recently, we have described immunophenotypic features in JMML at diagnosis. Here, our aim was to examine the changes in the immunophenotypic features during azacitidine treatment, correlating it with clinical response. Patients treated with 5-azacitidine were evaluated at diagnosis and after three and six cycles of medication. Among 32 patients entering the study, 28 patients were examined after three cycles and 25 patients after six. Patients showed a reduction in CD34/CD117+ cells: median 3.35% at diagnosis, 2.8% after three cycles and 1.63% after six. B-cell progenitors were decreased at diagnosis and decreased after treatment. Monocytes decreased: 11.91% to 6.4% and 4.18% respectively. Complete response was associated with increase in classical monocytes. T lymphocytes, reduced at diagnosis, increased in patients responding to 5-azacitidine. Immunophenotypic aberrancies including expression of CD7 in myeloid progenitors remained after treatment. This feature was associated with a worse response to treatment, as well as presence of NF1. Immunophenotyping was feasible in all patients. Clinical response was associated with a decrease of myeloid progenitors and monocytes and a rise in T lymphocytes although phenotypic aberrancies persisted. The largest effect was observed after three cycles.

Citação
Oliveira AF, Tansini A, Toledo T, Balceiro R, Lee MLM, Villela N, Ikeuty P, Metze K, Lopes LF, Lorand-Metze I. Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response? Br J Haematol. 2022 May;197(3):339-348. Spanish. doi: 10.1111/bjh.18089. Epub 2022 Feb 21. PMID: 35187646.

Data documento
15/12/2020

Título
Intervenção da enfermagem frente à neutropenia febril em pacientes oncológicos adultos: uma revisão integrativa da literatura.

Autor(es)
INACIO, J.P.R. - PAIVA, L.C.

Palavras chave
Oncologia - Quimioterapia - Neutropenia Febril - Assistência de Enfermagem

Resumo
INTRODUÇÃO: Embora a quimioterapia apresente resultados positivos no tratamento de pacientes oncológicos, esta modalidade terapêutica é, também, bastante conhecida em função dos efeitos colaterais e reações adversas que acarretam aos pacientes, incluindo entre estas a neutropenia febril. OBJETIVOS: Analisar a literatura científica produzida sobre assistência de enfermagem ao paciente adulto oncológico com neutropenia febril; identificar as principais intervenções de enfermagem no manejo da NF induzida por quimioterapia e, demonstrar a importância das intervenções de enfermagem para identificação dos fatores de risco, prevenção e tratamento da NF. MATERIAL E MÉTODOS: Considerando seus objetivos, este estudo classifica-se como descritivo qualiquantitativo. Sendo o método adotado para realização deste a revisão integrativa da literatura. O presente estudo teve como questão norteadora: “Quais são as intervenções de enfermagem no cuidado ao paciente adulto oncológico em neutropenia febril, descritas na literatura?”. RESULTADOS: A busca na base de dados BVS resultou num total de 125 publicações. Após submissão destas aos critérios de inclusão pré-definidos no estudo restaram 19 artigos para compor a discussão desta pesquisa. As publicações analisadas consideram que as intervenções de enfermagem são fundamentais para a evolução satisfatória da paciente em relação à neutropenia febril. CONSIDERAÇÕES FINAIS: As intervenções de enfermagem no cuidado ao paciente com neutropenia febril compreendem: à manutenção das precauções padrões, avaliação dos fatores de risco para neutropenia febril; educação sobre autocuidado, educação permanente e consulta ambulatorial periódica.

Descrição
Trabalho de Conclusão de Curso de Especialização em Enfermagem em Oncologia

Citação
INÁCIO, Juliana Paulista Ribeiro; PAIVA, Laís Cristina. Intervenção da enfermagem frente à neutropenia febril em pacientes oncológicos adultos: uma revisão integrativa da literatura. Trabalho de Conclusão de Curso de Especialização em Enfermagem em Oncologia. Barretos: Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata; 2020.

Data documento
06/05/2024

Título
Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer

Autor(es)
Freitas A.J.A. - Causin R - L. - Varuzza M.B. - Calfa S. - Hidalgo Filho C.M.T. - Komoto T.T. - Souza C.P. - Marques M.M.C.

Palavras chave
breast cancer - liquid biopsy - precision medicine

Resumo
Breast cancer (BC) is a highly heterogeneous disease. The treatment of BC is complicated owing to intratumoral complexity. Tissue biopsy and immunohistochemistry are the current gold standard techniques to guide breast cancer therapy; however, these techniques do not assess tumoral molecular heterogeneity. Personalized medicine aims to overcome these biological and clinical complexities. Advances in techniques and computational analyses have enabled increasingly sensitive, specific, and accurate application of liquid biopsy. Such progress has ushered in a new era in precision medicine, where the objective is personalized treatment of breast cancer, early screening, accurate diagnosis and prognosis, relapse detection, longitudinal monitoring, and drug selection. Liquid biopsy can be defined as the sampling of components of tumor cells that are released from a tumor and/or metastatic deposits into the blood, urine, feces, saliva, and other biological substances. Such components include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) or circulating tumor RNA (ctRNA), platelets, and exosomes. This review aims to highlight the role of liquid biopsy in breast cancer and precision medicine.

Citação
Freitas AJA, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, Souza CP, Marques MMC. Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. Int J Mol Sci. 2022 Sep 1;23(17):9952. doi: 10.3390/ijms23179952. PMID: 36077348; PMCID: PMC9456236.

Data documento
06/05/2024

Título
Management of Early-Stage Vulvar Cancer

Autor(es)
Pedrão P.G. - Guimarães Y.M. - Godoy L.R. - Possati-Resende J.C. - Bovo A.C. - Andrade C.E.M.C. - Longatto-Filho A. - Dos Reis R.

Palavras chave
vulvar cancer - vulvar neoplasms - diagnosis and staging - sentinel lymph node

Resumo
Vulvar cancer is a rare gynecological malignancy since it represents 4% of all cancers of the female genital tract. The most common histological type is squamous cell carcinoma (90%). This type can be classified into two clinicopathological subtypes according to the etiology. The first subtype is associated with persistent human papillomavirus infection and is usually diagnosed in younger women. The second subtype is associated with lichen sclerosus condition, and in most cases is diagnosed in postmenopausal women. Currently, an increase in first subtype cases has been observed, which raised the concern about associated mortality and treatment morbidity among young women. Vulvar cancer treatment depends on histopathology grade and staging, but surgery with or without radiotherapy as adjuvant treatment is considered the gold standard. In recent decades, sentinel lymph node biopsy has been incorporated as part of the treatment. Therefore, we sought to review and discuss the advances documented in the literature about vulvar cancer focusing on the treatment of early-stage disease. Relevant articles, such as the GROINS-V studies and the GOG protocols, are presented in this review. Additionally, we discuss key points such as the evolution of treatment from invasive surgery with high morbidity, to more conservative approaches without compromising oncologic safety; the role of sentinel lymph node mapping in the initial staging, since it reduces the complications caused by inguinofemoral lymphadenectomy; the recurrences rates, since local recurrence is common and curable, however, groin-associated, or distant recurrences have a poor prognosis; and, finally, the long-term follow-up that is essential for all patients.

Citação
Pedrão PG, Guimarães YM, Godoy LR, Possati-Resende JC, Bovo AC, Andrade CEMC, Longatto-Filho A, Dos Reis R. Management of Early-Stage Vulvar Cancer. Cancers (Basel). 2022 Aug 29;14(17):4184. doi: 10.3390/cancers14174184. PMID: 36077719; PMCID: PMC9454625.

Data documento
15/12/2020

Título
Manejo da dor aguda em pacientes oncológicos pediátricos – Revisão Bibliográfica

Autor(es)
TAVARES, L.M.

Palavras chave
Dor - Oncologia - Paciente pediátrico

Resumo
JUSTIFICATIVA: Os pacientes oncológicos pediátricos vivenciam várias formas de desconfortos quando submetidos à tratamentos para tais neoplasias, além da dor do próprio tumor, são expostos a vários tipos de dores, entre elas a dor aguda. OBJETIVO: Mostrar as dificuldades dos profissionais da saúde para avaliação através das escalas específicas para as determinadas idades, compreendendo os danos causados pela dor aguda. E também ressaltar os manejos farmacológicos e não farmacológicos para minimizá-la. MATERIAIS E MÉTODOS: Refere-se a uma Revisão Bibliográfica, realizada nas bases de dados Scientific Electronic Library Online (SciELO), PubMed e Cochrane Library. Aplicou-se os seguintes descritores para realização da estratégia de busca: Acute Pains, Neoplasms, Child, também utilizado Estratégias Farmacológicas e Não Farmacológicas para Dor Aguda como termo livre. Os critérios de inclusão empregados foram: artigos livres para acesso; língua portuguesa ou inglesa; publicados de janeiro de 2010 a agosto de 2020. E os critérios de exclusão: artigos que abordem manejo da dor em pacientes com idade maior que 12 anos; artigos que apresentem somente resumo disponível. RESULTADOS: Baseado na estratégia de busca, chegou-se ao total de 31 artigos, onde 27 foram descartados por não atenderem os critérios de inclusão e 4 retirados por conta dos critérios de exclusão. CONCLUSÃO: Poucos artigos encontrados através da busca atenderam às expectativas propostas, existe uma grande dificuldade a respeito desse tema, principalmente para o manejo da dor aguda não farmacológico para pacientes pediátricos.

Descrição
Trabalho de Conclusão de Curso de Especialização em Enfermagem em Oncologia

Citação
TAVARES, Lívia Macedo. Manejo da dor aguda em pacientes oncológicos pediátricos – Revisão Bibliográfica. Trabalho de Conclusão de Curso de Especialização em Enfermagem em Oncologia. Barretos: Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata; 2020.

Data documento
06/05/2024

Título
Maternal Low-Protein Diet Deregulates DNA Repair and DNA Replication Pathways in Female Offspring Mammary Gland Leading to Increased Chemically Induced Rat Carcinogenesis in Adulthood

Autor(es)
Zapaterini J.R. - Fonseca A.R.B. - Bidinotto L.T. - Colombelli K.T. - Rossi A.L.D. - Kass L. - Justulin L.A. - Barbisan L.F.

Palavras chave
DNA damage - DNA repair and replication - N-methyl-N-nitrosourea - female Sprague–Dawley - maternal low protein intake - perinatal programming - risk for mammary carcinogenesis

Resumo
Studies have shown that maternal malnutrition, especially a low-protein diet (LPD), plays a key role in the developmental mechanisms underlying mammary cancer programming in female offspring. However, the molecular pathways associated with this higher susceptibility are still poorly understood. Thus, this study investigated the adverse effects of gestational and lactational low protein intake on gene expression of key pathways involved in mammary tumor initiation after a single dose of N-methyl-N-nitrosourea (MNU) in female offspring rats. Pregnant Sprague-Dawley rats were fed a normal-protein diet (NPD) (17% protein) or LPD (6% protein) from gestational day 1 to postnatal day (PND) 21. After weaning (PND 21), female offspring (n = 5, each diet) were euthanized for histological analysis or received NPD (n = 56 each diet). At PND 28 or 35, female offspring received a single dose of MNU (25 mg/kg body weight) (n = 28 each diet/timepoint). After 24 h, some females (n = 10 each diet/timepoint) were euthanized for histological, immunohistochemical, and molecular analyses at PDN 29 or 36. The remaining animals (n = 18 each diet/timepoint) were euthanized when tumors reached ≥2 cm or at PND 250. Besides the mammary gland development delay observed in LPD 21 and 28 groups, the gene expression profile demonstrated that maternal LPD deregulated 21 genes related to DNA repair and DNA replication pathways in the mammary gland of LPD 35 group after MNU. We further confirmed an increased γ-H2AX (DNA damage biomarker) and in ER-α immunoreactivity in mammary epithelial cells in the LPD group at PND 36. Furthermore, these early postnatal events were followed by significantly higher mammary carcinogenesis susceptibility in offspring at adulthood. Thus, the results indicate that maternal LPD influenced the programming of chemically induced mammary carcinogenesis in female offspring through increase in DNA damage and deregulation of DNA repair and DNA replication pathways. Also, Cidea upregulation gene in the LPD 35 group may suggest that maternal LPD could deregulate genes possibly leading to increased risk of mammary cancer development and/or poor prognosis. These findings increase the body of evidence of early-transcriptional mammary gland changes influenced by maternal LPD, resulting in differential response to breast tumor initiation and susceptibility and may raise discussions about lifelong prevention of breast cancer risk.

Citação
Zapaterini JR, Fonseca ARB, Bidinotto LT, Colombelli KT, Rossi ALD, Kass L, Justulin LA, Barbisan LF. Maternal Low-Protein Diet Deregulates DNA Repair and DNA Replication Pathways in Female Offspring Mammary Gland Leading to Increased Chemically Induced Rat Carcinogenesis in Adulthood. Front Cell Dev Biol. 2022 Feb 1;9:756616. doi: 10.3389/fcell.2021.756616. PMID: 35178394; PMCID: PMC8844450.

Data documento
06/05/2025

Título
O uso excessivo de telas pode levar ao Alzheimer?

Autor(es)
Anna Clara Vitolo T. L. F. Siqueira

Palavras chave
Alzheimer - Demência digital - uso de telas

Descrição
Orientadora: Prof.ª Adriana Paula Sanchez Schiaveto

Data documento
11/04/2024

Título
Regulamento para Implantação do Acervo em Meio Digital

Autor(es)
Comitê gestor do acervo em meio digital.

Resumo
O acervo acadêmico é composto pelos documentos dos alunos, docentes, do controle e registro acadêmico, do curso e coordenações de curso, da mantida e da mantenedora. O acervo acadêmico digital é o escaneamento dos arquivos físicos da Instituição. Com a transformação digital o setor educacional precisou rever velhas práticas. Desde 1990 com a publicação da Portaria SESU/SENESU nº 255 de 20 de dezembro daquele ano, o Ministério da Educação apontou caminhos de mudanças para a virtualização do acervo acadêmico e ao longo desse tempo se descobre o grande desafio para as Instituições de Ensino Superior.

Citação
Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata - FACISB

Data documento
02/05/2024

Título
The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models

Autor(es)
Teixeira, S.A. - Luzzi, M.d.C. - Martin, A.C.B.M. - Duarte, T.T. - Leal, M.d.O. - Teixeira, G.R. - Reis, M.T. - Junior, C.R.A. - Santos, K. - Melendez, M.E. - et al.

Palavras chave
PTCH1-knockout - ApcMin - xenografts - PDX - genetically engineered mouse models - personalized therapy - tumor biology

Resumo
The Barretos Cancer Hospital Animal Facility (BCHAF) is a unique facility in Brazil exclusively dedicated to working with animal models for cancer research. In this article, we briefly present our modern facility and the main experiments performed, focusing on mutant strains of mice (PTCH-knockout and ApcMin mice), xenograft models, and patient-derived xenografts (PDXs). Our results show the progress and challenges in establishing these models and the need for having an appropriate representation of our cancer population to better understand tumor biology and to identify cancer biomarkers, which could be putatively targeted, allowing for personalized therapy

Citação
Teixeira, S.A.; Luzzi, M.d.C.; Martin, A.C.B.M.; Duarte, T.T.; Leal, M.d.O.; Teixeira, G.R.; Reis, M.T.; Junior, C.R.A.; Santos, K.; Melendez, M.E.; et al. The Barretos Cancer Hospital Animal Facility: Implementation and Results of a Dedicated Platform for Preclinical Oncology Models. Vet. Sci. 2022, 9, 636. https://doi.org/10.3390/vetsci9110636